A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

Pneumococcal disease remains a public health priority worldwide. This phase 2 study (V114-008; NCT02987972; EudraCT 2016-001117-25) compared safety and immunogenicity of 2 clinical lots of V114 (investigational 15-valent pneumococcal vaccine: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F*, 23F,...

Descripción completa

Detalles Bibliográficos
Autores principales: Platt, Heather L., Greenberg, David, Tapiero, Bruce, Clifford, Robert A., Klein, Nicola P., Hurley, David C., Shekar, Tulin, Li, Jianing, Hurtado, Kim, Su, Shu-Chih, Nolan, Katrina M., Acosta, Camilo J., McFetridge, Richard D., Bickham, Kara, Musey, Luwy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Vaccine Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360095/
https://www.ncbi.nlm.nih.gov/pubmed/32639460
http://dx.doi.org/10.1097/INF.0000000000002765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360095/
https://www.ncbi.nlm.nih.gov/pubmed/32639460
http://dx.doi.org/10.1097/INF.0000000000002765

Ejemplares similares